---
id: aan-dementia-2024
title: "AAN 2024 Practice Guideline Update: Mild Cognitive Impairment and Dementia"
short_title: "AAN Dementia 2024"

organization: American Academy of Neurology
collaborators: null
country: US
url: https://www.aan.com/Guidelines/
doi: null
pmid: null
open_access: true

specialty: neurology
guideline_type: clinical-practice
evidence_system: AAN
conditions:
  - dementia
  - mild cognitive impairment
  - Alzheimer disease
tags:
  - cognitive screening
  - cholinesterase inhibitors
  - memantine
  - lecanemab
  - caregiver support

publication_date: 2024-05-01
previous_version_date: 2018-01-01
status: current
supersedes: null
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-24
---

## Scope
2024 AAN practice guideline update on the evaluation and management of mild cognitive impairment (MCI) and dementia, including Alzheimer disease.

## Key Recommendations

### Evaluation
- Obtain a thorough history (patient and informant), cognitive testing (e.g., MoCA, Mini-Cog, MMSE), and neurological examination.
- **Labs**: Rule out reversible causes: TSH, B12, CBC, CMP. Consider RPR, HIV if risk factors.
- **Neuroimaging**: MRI brain preferred to exclude structural causes (stroke, tumor, hydrocephalus) and assess atrophy pattern.
- **Biomarkers**: Amyloid PET or CSF AÎ²42/tau may be used to confirm Alzheimer pathology in atypical or unclear cases, or for disease-modifying therapy eligibility.

### Pharmacotherapy for Alzheimer Disease

#### Cholinesterase Inhibitors
- Donepezil, rivastigmine, galantamine are recommended for mild-to-moderate Alzheimer disease. Modest symptomatic benefit.

#### Memantine
- NMDA receptor antagonist. May be added for moderate-to-severe Alzheimer disease.

#### Anti-Amyloid Monoclonal Antibodies
- **Lecanemab (Leqembi)**: FDA approved for early Alzheimer disease (MCI or mild dementia due to AD) with confirmed amyloid pathology. Slows cognitive and functional decline. Requires amyloid PET or CSF confirmation; regular MRI monitoring for ARIA (amyloid-related imaging abnormalities).
- **Donanemab**: Under FDA review; similar mechanism.

### Non-Pharmacological Management
- Cognitive stimulation, exercise, social engagement.
- Occupational therapy for functional adaptation.
- Advance care planning.

### Caregiver Support
- Assess caregiver burden. Refer to support resources (Alzheimer's Association, respite care).
